Trial Selection Process

Slides:



Advertisements
Similar presentations
Are all COX-2 medicines the same? Pharmacokinetics and metabolism of coxibs t max (h) Bioavailabili ty (oral, %) t 50% (h) Primary metabolism 5 (cytochrome.
Advertisements

Description of Each Study in the Cross Trial Safety Analysis Solomon SD, et al. Circulation 2008 [Epub Mar 31]
NSAIDS in the ischaemic heart disease patient
Canadian Cardiovascular Society Antiplatelet Guidelines
VBWG IDEAL: The Incremental Decrease in End Points Through Aggressive Lipid Lowering Study.
Copyright restrictions may apply JAMA Ophthalmology Journal Club Slides: Elevated Intraocular Pressure After Intravitreal Triamcinolone Acetonide Aref.
6 / 5 / RENAL DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED INTO 3 GROUPS BY BASELINE GLOMERULAR FILTRATION RATE (GFR) ALLHAT.
Randomized, double-blind, multicenter, controlled trial.
Antidepressants and Suicidality in Adults: Statistical Evaluation Mark Levenson, Ph.D.* and Chris Holland, M.S. Statistical Safety Reviewers Quantitative.
Complications of the COX-2 Inhibitors Parecoxib and Valdecoxib after Cardiac Surgery Nancy A. Nussmeier, M.D., Andrew A. Whelton, M.D., Mark T. Brown,
Safety of Cyclooxygenase-2 (COX-2) inhibitors, Valdecoxib and Parecoxib, versus Placebo for Post CABG Pain Management Presented at American College of.
PH 401: Meta-analysis Eunice Pyon, PharmD (718) , HS 506.
Enrollment, Randomization, and Follow-up of Study Participants ADVANCE Collaborative Group. N Engl J Med 2008;358:
Cardiovascular Risk and NSAIDs Arthritis Advisory Committee Meeting April 12, 2007 Sharon Hertz, M.D. Deputy Director Division of Analgesia, Anesthesia,
Background There are 12 different types of medications to lower blood sugar levels in patients with type 2 diabetes. It is widely agreed upon that metformin.
Participant Characteristics by Lowest Leg AAI Category Ann M. O’Hare, et al, Circulation 2006;113;
Small Bowel Toxicity of Nonselective NSAIDs Revealed by Capsule Endoscopy: Results From a Pivotal Clinical Trial Glenn M. Eisen, M.D., M.P.H. Associate.
Flow Diagram of Identification of Randomized Trials for Inclusion Goran Bjelakovic, et al. JAMA. 2007;297:
Date of download: 5/30/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Aspirin for the Prevention of Cardiovascular Events.
Date of download: 5/31/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Estrogen Plus Progestin and Breast Cancer Incidence.
Date of download: 6/21/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Low-Dose Aspirin for Primary Prevention of Cardiovascular.
Beaver Dam Eye Study: Overall Participant Flow Barbara E. K. Klein, et al. JAMA 2006;295:
What should the Systolic BP treatment goal be in patients with CKD?
Flow of Individuals Through the Vitamin E and Vitamin C Components of the Physicians’ Health Study II Howard D. Sesso et al. JAMA 2008;300:
Safety risks for patients with aspirin-exacerbated respiratory disease after acute exposure to selective nonsteroidal anti-inflammatory drugs and COX-2.
Copyright © 2000 American Medical Association. All rights reserved.
Meta-Analysis of a Possible Signal of Increased Mortality Associated with Cefepime Use Peter W. Kim, Yu-te Wu, Charles Cooper, George Rochester, Thamban.
Copyright © 2012 American Medical Association. All rights reserved.
Copyright © 2014 American Medical Association. All rights reserved.
Why wasn’t a beta-blocker tested as first-line therapy?
HS4160 Critical Scientific Analysis
Selection of NSAIDs for Osteoarthritis
Nurses' Health Study: Risk of hypertension associated with >1000 µg/day of folate vs
JAMA Ophthalmology Journal Club Slides: Effect of Oral Voriconazole on Fungal Keratitis Prajna NV, TKrishnan T, Rajaraman R, et al; Mycotic Ulcer Treatment.
GAUSS-3 Trial design: Patients with objective evidence of intolerance to statin agents were randomized in a 2:1 fashion to either evolocumab 420 mg subcutaneously.
Results of random-effects meta-analysis of association between use of angiotensin-converting-enzyme (ACE) inhibitors or angiotensin-receptor blockers and.
Systolic Blood Pressure Intervention Trial (SPRINT)
GLAGOV Trial design: Patients with CAD and elevated LDL cholesterol on statin therapy were randomized to subcutaneous evolocumab (n = 484) vs. subcutaneous.
NSAIDs: Risk of acute MI compared with remote use
Effect of beta-blockers on perioperative outcomes in vascular and endovascular surgery: a systematic review and meta-analysis  S Hajibandeh, S Hajibandeh,
بعض النقاط التي تؤخذ في الحسبان عند تقييم الاستثمارات الزراعية
Drug Rate ratio 95% CI Thiazide diuretics 1.0 Reference ACE inhibitors
MTX Lung vs. Rheumatoid Lung Disease
Insights from the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT)
Trial analysis results comparing ACE inhibitors/ARBs with other antihypertensive drugs on renal disease progression End point Relative risk (95% CI) p.
Safety risks for patients with aspirin-exacerbated respiratory disease after acute exposure to selective nonsteroidal anti-inflammatory drugs and COX-2.
Relative risk of major events with atenolol vs placebo
Outcome Relative risk with beta blockers 95% CI Stroke –1.30
Jun M, et al. Lancet 2010 Epub May 10
Risk of perioperative renal dysfunction with N-acetylcysteine or placebo in patients undergoing CABG surgery End point N-acetylcysteine Placebo Relative.
Description of studies for pooled analyses
Fung TT, et al. Circulation 2009;119:
Gastrointestinal Effects of NSAIDs and Coxibs
Volume 135, Issue 5, Pages (November 2008)
Early Aquatic Physical Therapy Improves Function and Does Not Increase Risk of Wound-Related Adverse Events for Adults After Orthopedic Surgery: A Systematic.
Volume 81, Issue 7, Pages (April 2012)
Relative risk reduction for incident hypertension associated with weight loss of 6.8 kg: The Framingham Study Cohort Risk reduction (%) Relative risk.
Suprarenal versus infrarenal stent graft fixation on renal complications after endovascular aneurysm repair  Larry E. Miller, PhD, Mahmood K. Razavi,
Berger JS, et al. JAMA 2009;301:
Flow of Patients Through the Trial
Flow of Patients Through Trial
Flow diagram for exclusions of trials identified RCT indicates randomized controlled trial Hulten E, et al. Arch Intern Med 2006;166:
Participation in Japanese Primary Prevention of Atherosclerosis With Aspirin for Diabetes (JPAD) Trial Hisao Ogawa et al. JAMA 2008;300:
Relative Risk of Onset of Cancer from the Cholesterol Treatment Trialists’ (CTT) Meta-Analysis of Statin Trials, According to Year of Onset Risk ratios.
Results of Searches and Screening of Potentially Relevant Studies
Kaplan–Meier plots of 5 and 12-year all cause (A and C, respectively) and cardiovascular mortality (B and D, respectively) with number of participants.
Overall forest plot from meta-analysis carried out in 11 studies a) assessing the relative risk of adverse events; and subgroup analysis performed on studies.
HRs (and 95% CIs) for incident type 2 diabetes for a doubling of total flavonoid (A) and lignan (B) intakes across countries in the InterAct study. HRs.
HRs for type 2 diabetes by category of age at menarche in the EPIC-InterAct study. HRs for type 2 diabetes by category of age at menarche in the EPIC-InterAct.
Pooled estimate of relative risk and 95% CIs of colorectal cancer associated with metformin therapy based on four studies comprising 107,961 diabetic patients.
Presentation transcript:

Trial Selection Process Jingjing Zhang, et al. JAMA. 2006;296:1619-1632

Included Trials of Rofecoxib* Jingjing Zhang, et al. JAMA. 2006;296:1619-1632

Included Trials of Celecoxib* Jingjing Zhang, et al. JAMA. 2006;296:1619-1632

Included Trials of Valdecoxib and Parecoxib* Jingjing Zhang, et al. JAMA. 2006;296:1619-1632

Included Trials of Etoricoxib and Lumiracoxib Jingjing Zhang, et al. JAMA. 2006;296:1619-1632

Descriptive Characteristics of Included Randomized Double-Blind Clinical Trials of Cyclooxygenase 2 Inhibitors Jingjing Zhang, et al. JAMA. 2006;296:1619-1632

Number of Arrhythmia Events by Reported Subtypes Jingjing Zhang, et al. JAMA. 2006;296:1619-1632

Overall Relative Risks of Renal and Arrhythmia Events, Cyclooxygenase 2 Inhibitors vs Controls Jingjing Zhang, et al. JAMA. 2006;296:1619-1632

Relative Risk of Composite Renal Events (Renal Dysfunction, Peripheral Edema, Hypertension) by COX-2 Inhibitors, Meta-Regression Stratified by Study Characteristics Jingjing Zhang, et al. JAMA. 2006;296:1619-1632

Time-Cumulative Analysis of Rofecoxib and Risk of Renal and Arrhythmia Events Sensitivity analyses of the 9 trials with 20300 participants (10126 drug, 10174 control group) and 15 arrhythmia events (13 drug, 2 control group) without half-integer correction using sparse-events exact methods: Fisher exact test P =.004, and Mantel-Haenszel pooled relative risk 6.52 (95% CI, 1.48-28.8; P=.004) Jingjing Zhang, et al. JAMA. 2006;296:1619-1632

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2025 SlidePlayer.com. Inc. All rights reserved.